Faculty profile

Caroline Hamm

ResearcherUniversity of Windsor

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Windsor directory, so their courses and email address may be missing. Find their university profile.

Caroline Hamm

Researcher

Health Sciences

University of Windsor

Windsor, Ontario, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
32 publications in the last five years, latest in 2026.
Senior (last) author on 10 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

146

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Barriers To Clinical Trials Clinical Trials Acrrual Equity Of Access Implementation Science Oncology Pragmatic Wedge-Step Cluster Randomization

Latest papers

Toxicities of CAR-T, Bispecific Antibodies, and Antibody-Drug Conjugates in Multiple Myeloma: A Practical Approach to Risk Mitigation and Management.
Cancers · 2026
Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.
Current oncology (Toronto, Ont.) · 2026 · senior author
Connecting Patients with Clinical Trials Using Patient Navigation: A Scoping Review.
Current oncology (Toronto, Ont.) · 2026

All 67 publications

Latest funding

Enhancing the Patient Journey to Clinical Trial Enrolment with Navigation to Optimize Accrual: A Pilot Study for a pragmatic multi-centre, stepped wedge, cluster randomized controlled trial (The CTN Pilot Trial)
CIHR · 2023 · Nominated PI
$198,825
Novel Cell Cycle Regulation in the Initiation and Therapeutic Intervention of Breast Cancer
CIHR · 2015 · Co-investigator
$765,202
Differential affects of personal and community resources on breast cancer care and long-term survival in Canada and the United States, 1995 to 2015
CIHR · 2009 · Co-investigator
$346,054

All 3 grants and awards

67 publications.

Toxicities of CAR-T, Bispecific Antibodies, and Antibody-Drug Conjugates in Multiple Myeloma: A Practical Approach to Risk Mitigation and Management.

Hej-Ali S, Banwell K, Mohamed H, Cervi A, Dass A, Gupta R, Hamm C, Kanjeekal S, Strange Seguel I, Szalay M, Khan S

Cancers2026

DOI: 10.3390/cancers18132083 PMID: 42449627

Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

Boujeke EJ, Catalan A, Arayan L, Mina AP, James-McDonald CE, Gupta R, Kulkarni S, Nasser A, Chowdhury D, Brackstone M, Mathews J, Hamm C

Current oncology (Toronto, Ont.)2026Senior author

DOI: 10.3390/curroncol33090513 PMID: 42782860

Connecting Patients with Clinical Trials Using Patient Navigation: A Scoping Review.

Hilal O, Patel R, Gupta P, Askin N, Ivankovic V, Epp C, Nassar R, Paunic M, Hossami M, Abdel-Nabi R, Touma M, Sadik G, Jaet A, Trieu C, Mohamed I, Anagnostopoulos G, Yoo L, El Hindawi M, Hamm C, Delisle M

Current oncology (Toronto, Ont.)2026

DOI: 10.3390/curroncol33060341 PMID: 42346241

Implementing a national clinical trial navigator program: a qualitative CFIR analysis of barriers and facilitators from the perspective of people with lived cancer experience.

Luginaah NA, Alhajsaleh S, Anagnostopoulos G, Paunic M, Inglis D, Boujeke E, Sharma D, Nassar R, Hilal O, Mohamed I, Gupta P, Trieu C, Patel R, Touma M, Sadik G, Jaet A, Kalia S, Raheem AA, Abdel-Nabi R, Arayan L, Almasri L, Shen NZ, Yoo L, McGrath L, Hamm C, Delisle M

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026

DOI: 10.1007/s00520-026-10455-x PMID: 41723326

Redefining 'normal': A Canadian case study of cancer survivors' experiences remaining and/or returning to work during the COVID-19 pandemic.

Tran C, Kane D, Rajacich D, Lafreniere K, Hamm C

PloS one2026Senior author

DOI: 10.1371/journal.pone.0342935 PMID: 41686805

Patient perspective of Hesitancies and strategies to increase cancer clinical trial participation.

Fifield BA, Baker A, Elkhidir O, Philbin N, Hinch I, McVinnie N, Llancari A, Pecoraro C, Rahimi M, Visconti T, Shoust A, McMurphy S, Soucie K, Hamm C, Porter LA

Journal of clinical and translational science2026

DOI: 10.1017/cts.2026.10695 PMID: 41822554

Pilot study: A prospective, real-world, feasibility study testing a decreased frequency paradigm in treatment free remission in chronic myeloid leukemia.

Ravipati S, Bakheet W, Woldie I, Gupta R, Yousif G, Faraj H, Hussein A, Luo R, Cervi A, Gupta G, Kanjeekal S, Khan S, Hamm C

Leukemia research2025Senior author

DOI: 10.1016/j.leukres.2025.108087 PMID: 40850166

Optimizing Adjuvant Care in Early Breast Cancer: Multidisciplinary Strategies and Innovative Models from Canadian Centers.

Chan A, Nixon N, Al-Khaifi M, Bestavros A, Blyth C, Cheung WY, Hamm C, Joly-Mischlich T, Manna M, McFarlane T, Minard LV, Naujokaitis S, Peragine C, Railton C, Edwards S

Current oncology (Toronto, Ont.)2025

DOI: 10.3390/curroncol32070402 PMID: 40710212

Cross sectional analysis of clinical trials search results for cancer patients using a navigator-assisted clinical trials search using five different search engines.

Paunic M, Rim S, Hilal O, Nassar R, Driedger Z, Zaib F, Touma K, Hossami M, Abdel-Nabi R, Hirmiz R, Hamm C

PloS one2025Senior author

DOI: 10.1371/journal.pone.0326139 PMID: 40560909

Clinical Significance of Tumor Grade in Triple-Negative Breast Cancer: A Retrospective Cohort Analysis.

Ramanan N, Malik MN, Upneja S, Farooq H, Kulkarni S, Gupta R, Mathews J, Nasser A, Bocicariu A, Arayan L, Porter L, Fifield BA, Luo R, Brackstone M, Hamm C

Biomedicines2025Senior author

DOI: 10.3390/biomedicines13051100 PMID: 40426927

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2023

Subject: Prospective PhD student: Barriers To Clinical Trials Dear Professor Hamm, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Toxicities of CAR-T, Bispecific Antibodies, and Antibody-Drug Conjugates in Multiple Myeloma: A Practical Approach to Risk Mitigation and Management." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "Enhancing the Patient Journey to Clinical Trial Enrolment with Navigation to Optimize Accrual: A Pilot Study for a pragmatic multi-centre, stepped wedge, cluster randomized controlled trial (The CTN Pilot Trial)" (2023), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Caroline Hamm

Research

Latest papers

Latest funding

Toxicities of CAR-T, Bispecific Antibodies, and Antibody-Drug Conjugates in Multiple Myeloma: A Practical Approach to Risk Mitigation and Management.

Real-World Toxicities and Outcomes of Pembrolizumab in Early-Stage Triple-Negative Breast Cancer.

Connecting Patients with Clinical Trials Using Patient Navigation: A Scoping Review.

Implementing a national clinical trial navigator program: a qualitative CFIR analysis of barriers and facilitators from the perspective of people with lived cancer experience.

Redefining 'normal': A Canadian case study of cancer survivors' experiences remaining and/or returning to work during the COVID-19 pandemic.

Patient perspective of Hesitancies and strategies to increase cancer clinical trial participation.

Pilot study: A prospective, real-world, feasibility study testing a decreased frequency paradigm in treatment free remission in chronic myeloid leukemia.

Optimizing Adjuvant Care in Early Breast Cancer: Multidisciplinary Strategies and Innovative Models from Canadian Centers.

Cross sectional analysis of clinical trials search results for cancer patients using a navigator-assisted clinical trials search using five different search engines.

Clinical Significance of Tumor Grade in Triple-Negative Breast Cancer: A Retrospective Cohort Analysis.

Enhancing the Patient Journey to Clinical Trial Enrolment with Navigation to Optimize Accrual: A Pilot Study for a pragmatic multi-centre, stepped wedge, cluster randomized controlled trial (The CTN Pilot Trial)

Novel Cell Cycle Regulation in the Initiation and Therapeutic Intervention of Breast Cancer

Differential affects of personal and community resources on breast cancer care and long-term survival in Canada and the United States, 1995 to 2015

Frequent collaborators

Guangyong Zou

Brian Leber

Lambert Busque

Christopher Hillis

Nancy Heddle

Tzu-Fei Wang

Donald Arnold

Muriel Brackstone

Teresa Petrella

Eitan Amir

Kenneth Ng

Melanie Powis

John Hilton

James Mcnulty

Na Li

John Kelton

Mark Norman Levine

Mohammad Refaei

Eva Grunfeld

Mark Clemons

Lisa Porter

Doris Howell

Maureen Trudeau

Sudeep Shivakumar

Janet Dancey

Emily Rimmer